Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation

References

• de la Camara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8(1):e2016031.
   PubMedGoogle Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438.
   PubMed Web of Science ®Google Scholar
• Stern M, Hirsch H, Cusini A, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98(9):1013–1018.
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019;20(11):2666.
   Web of Science ®Google Scholar
• McBride JM, Sheinson D, Jiang J, et al. Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-Seropositive donor and CMV-Seronegative solid organ transplant recipients. Open Forum Infect Dis. 2019;6(2):ofz003.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-27.
   PubMed Web of Science ®Google Scholar
• Azevedo LS, Pierrotti LC, Abdala E, et al. Cytomegalovirus infection in transplant recipients. Clinics. 2015;70(7):515–523.
   PubMed Web of Science ®Google Scholar
• Styczynski J. Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther. 2018;7(1):1–16.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13512.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272.
   PubMed Web of Science ®Google Scholar
• Haidar G, Boeckh M, Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221(Suppl 1):S23–s31.
   PubMedGoogle Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–931.
   PubMed Web of Science ®Google Scholar
• Venton G, Crocchiolo R, Furst S, et al. Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin Microbiol Infect. 2014;20(2):160–166.
   PubMed Web of Science ®Google Scholar
• Lumbreras C, Manuel O, Len O, et al. Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):19–26.
   PubMed Web of Science ®Google Scholar
• Mehta Steinke SA, Alfares M, Valsamakis A, et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transpl Infect Dis. 2021;23(3):e13521.
   PubMed Web of Science ®Google Scholar
• Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation. 2016;100(10):e74–e80.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420–1426.
   PubMed Web of Science ®Google Scholar
• Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65(12):2628–2640.
   PubMed Web of Science ®Google Scholar
• Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22(2):162–170.
   PubMed Web of Science ®Google Scholar
• Heliovaara E, Husain S, Martinu T, et al. Drug-resistant cytomegalovirus infection after lung transplantation: Incidence, characteristics, and clinical outcomes. J Heart Lung Transplant. 2019;38(12):1268–1274.
   PubMed Web of Science ®Google Scholar
• Corp. MSD. PREVYMISTM 2020. [cited 2020 February 17]. Available from: https://www.merck.com/product/usa/pi_circulars/p/prevymis/prevymis_pi.pdf.
   Google Scholar
• Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703–1711.
   PubMed Web of Science ®Google Scholar
• Stoelben S, Arns W, Renders L, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int. 2014;27(1):77–86.
   PubMed Web of Science ®Google Scholar
• Linder KA, Kovacs C, Mullane KM, et al. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transpl Infect Dis. 2021;23(4):e13687.
   PubMedGoogle Scholar
• Roche. Cytovene® US Prescribing Information 2018. [2019 December 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209347lbl.pdf.
   Google Scholar
• Genentech. VALCYTE® US Prescribing Information 2018. [2019 December 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021304s012,022257s007lbl.pdf.
   Google Scholar
• Pfizer. Foscavir® US Prescribing Information 2017. [2019 December 12]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=6521.
   Google Scholar
• Fisher CE, Knudsen JL, Lease ED, et al. Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients. Clin Infect Dis. 2017;65(1):57–63.
   PubMed Web of Science ®Google Scholar
• Minces LR, Nguyen MH, Mitsani D, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother. 2014;58(1):128–135.
   PubMed Web of Science ®Google Scholar
• Takeda. Takeda’s LIVTENCITY (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies 2021. Available from: https://www.takeda.com/newsroom/newsreleases/2021/takeda-livtencity-maribavir-approved-by-us-fda/.
   Google Scholar
• Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2019;36(1):1–9.
   PubMed Web of Science ®Google Scholar
• Ueno R, Nishimura S, Fujimoto G, et al. The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan – a retrospective database study. Curr Med Res Opin. 2019;35(12):1–8.
   Web of Science ®Google Scholar
• Webb BJ, Harrington R, Schwartz J, et al. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation. Transpl Infect Dis. 2018;20(5):e12961.
   PubMed Web of Science ®Google Scholar
• Henderson R, Carlin D, Kohlhase K, et al. Multicenter US study of hospital resource utilization associated with cytomegalovirus-related readmission of renal and heart transplant patients. Transpl Infect Dis. 2001;3(Suppl. 2):57–59.
   PubMedGoogle Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Le Page AK, Jager MM, Kotton CN, et al. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation. 2013;95(12):1455–1460.
   PubMed Web of Science ®Google Scholar
• Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis. 2004;189(8):1355–1361.
   PubMed Web of Science ®Google Scholar
• El Haddad L, Ghantoji SS, Park AK, et al. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol. 2020;92(1):86–95.
   PubMed Web of Science ®Google Scholar
• Robin C, Hemery F, Dindorf C, et al. Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients. BMC Infect Dis. 2017;17(1):747.
   PubMed Web of Science ®Google Scholar
• Hakimi Z, Aballea S, Ferchichi S, et al. Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting. Transpl Infect Dis. 2017;19(5):e12732.
   Web of Science ®Google Scholar
• Avery RK, Silveira FP, Benedict K, et al. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the organ transplant infection prevention and detection study: a multi-year, multicenter prospective cohort study. Transpl Infect Dis. 2018;20(3):e12877.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–2636.
   PubMed Web of Science ®Google Scholar